Navigation Links
Would an 'anti-ketamine' also treat depression?
Date:11/18/2013

Philadelphia, PA, November 18, 2013 Thirteen years ago, an article in this journal first reported that the anesthetic medication, ketamine, showed evidence of producing rapid antidepressant effects in depressed patients who had not responded to prior treatments. Ketamine works by blocking one of the targets for the neurotransmitter glutamate in the brain, the N-methyl-D-aspartate (NMDA) glutamate receptor.

Now, a new study in Biological Psychiatry reports that enhancing, instead of blocking, that same target the NMDA glutamate receptor also causes antidepressant-like effects.

Scientists theorize that NMDA receptor activity plays an important role in the pathophysiology of depression, and that normalizing its functioning can, potentially, restore mood to normal levels.

Prior studies have already shown that the underlying biology is quite complex, indicating that both hyperfunction and hypofunction of the NMDA receptor is somehow involved. But, most studies have focused on antagonizing, or blocking, the receptor, and until now, studies investigating NMDA enhancement have been in the early phases.

Sarcosine is one such compound that acts by enhancing NMDA function. Collaborators from China Medical University Hospital in Taiwan and the University of California in Los Angeles studied sarcosine in an animal model of depression and, separately, in a clinical trial of depressed patients.

"We found that enhancing NMDA function can improve depression-like behaviors in rodent models and in human depression," said Dr. Hsien-Yuan Lane, the corresponding author on the article.

In the clinical portion of the study, they conducted a 6-week trial where 40 depressed patients were randomly assigned to receive sarcosine or citalopram (Celexa), an antidepressant already on the market that was used as a comparison drug. Neither the patients nor their doctors knew which one they were receiving.

Compared to citalopram, patients receiving sarcosine reported significantly improved mood scores, were more likely to experience relief of their depression symptoms, and were more likely to continue in the study. There were no major side effects in either group, but patients receiving citalopram reported more relatively minor side effects than the patients being treated with sarcosine.

"It will be important to understand how sarcosine, which enhances NMDA receptor function, produces the interesting effects reported in this study. There are ways that its effects, paradoxically, might converge with those of ketamine, a drug that blocks NMDA receptors," commented Dr. John Krystal, Editor of Biological Psychiatry. "For example, both compounds may enhance neuroplasticity, the capacity to remodel brain networks through experience. Also, both potentially attenuate signaling through NMDA receptors, ketamine with single doses and sarcosine, with long-term administration, by evoking an adaptive down regulation of NMDA receptors."

Better understanding the reported findings may help to advance the development of medication treatments for patients who do not respond to available treatments. This is an important goal, with estimates indicating that as many as half of all patients do not experience complete relief of their depression.


'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Related biology news :

1. War-related climate change would reduce substantially reduce crop yields
2. What would Batman eat?
3. Cooled coal emissions would clean air and lower health and climate-change costs
4. Experts believe plain packaging of tobacco products would cut smoking
5. New emissions standards would fuel shift from coal to natural gas
6. Cutting specific pollutants would slow sea level rise
7. Better tests for liver toxicity would mean more medicines -- and safer medicines -- for patients
8. The peoples choice: Americans would pay to help monarch butterflies
9. Ozone treated water v. lethal microbial material
10. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
11. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative ... ... Maldives Immigration ... Algeen (small picture on the right) have received the IAIR award for ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/20/2017)... 20, 2017 PMD Healthcare announces the release ... Wellness Management System (WMS), a remote, real-time lung health ... PMD Healthcare is a Medical Device, Digital Health, and ... to creating innovative solutions that empower people to improve ... focus, PMD developed the first ever personal spirometer, Spiro ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... ... in 10 categories with over 30 nominees and well as the first-year award ... new award and the event was hosted by CompanyWeek and Manufacturers Edge, among ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University of ... round funding to three startups through the UConn Innovation Fund. The $1.5 million ... startups affiliated with UConn. , The UConn Innovation Fund provides investments of up ...
(Date:4/21/2017)... ... , ... The AMA is happy to announce that $48,000 in scholarships will ... scholarships are created through funds donated by model aviation organizations and individuals, AMA members, ... AMA Scholarship Committee, which is made up of model aviation pilots and enthusiasts. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging technology-based businesses, recently earned a $77,518 grant from the ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI ...
Breaking Biology Technology: